SIOX
Income statement / Annual
Last year (2022), Sio Gene Therapies Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2022, Sio Gene Therapies Inc.'s net income was -$71.89 M.
See Sio Gene Therapies Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
03/31/2022 |
03/31/2021 |
03/31/2020 |
03/31/2019 |
03/31/2018 |
03/31/2017 |
03/31/2016 |
03/31/2015 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$53.40 M
|
$24.90 M
|
$47.11 M
|
$87.55 M
|
$141.41 M
|
$134.78 M
|
$76.64 M
|
$0.00
|
| General & Administrative
Expenses |
$18.16 M
|
$17.29 M
|
$22.06 M
|
$39.47 M
|
$71.91 M
|
$45.72 M
|
$56.52 M
|
$0.00
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$18.16 M
|
$17.29 M
|
$22.06 M
|
$39.47 M
|
$71.91 M
|
$45.72 M
|
$56.52 M
|
$0.00
|
| Other Expenses |
-$39,000.00 |
$10.36 M |
$1.36 M |
$5.62 M |
$211,000.00 |
-$369,000.00 |
$133.16 M |
$0.00 |
| Operating Expenses |
$71.56 M |
$42.20 M |
$69.17 M |
$127.02 M |
$213.32 M |
$180.50 M |
$133.16 M |
$0.00 |
| Cost And Expenses |
$71.56 M |
$42.20 M |
$69.17 M |
$127.02 M |
$213.32 M |
$180.50 M |
$133.16 M |
$0.00 |
| Interest Income |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$27,000.00 |
$799,000.00 |
$4.38 M |
$7.53 M |
$7.55 M |
$1.14 M |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$666,000.00
|
$2.47 M
|
$3.09 M
|
$2.45 M
|
$3.08 M
|
$249,000.00
|
$14,000.00
|
$0.00
|
| EBITDA |
-$70.94 M
|
-$29.37 M
|
$0.00
|
-$121.40 M
|
-$210.02 M
|
-$179.48 M
|
$0.00
|
$0.00
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$639,000.00
|
$1.67 M
|
-$4.38 M
|
-$1.91 M
|
-$7.33 M
|
-$1.51 M
|
$0.00
|
$0.00
|
| Income Before Tax |
-$71.63 M |
-$32.64 M |
-$72.19 M |
-$128.93 M |
-$220.65 M |
-$182.01 M |
-$133.16 M |
$0.00 |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$259,000.00 |
-$212,000.00 |
$438,000.00 |
$133,000.00 |
$921,000.00 |
-$1.06 M |
-$17,000.00 |
$0.00 |
| Net Income |
-$71.89 M |
-$32.43 M |
-$72.63 M |
-$129.07 M |
-$221.57 M |
-$180.95 M |
-$133.15 M |
$0.00 |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-0.98 |
-0.62 |
-2.93 |
-8.02 |
-16.51 |
-14.6 |
-11.28 |
0 |
| EPS Diluted |
-0.98 |
-0.62 |
-2.93 |
-8.02 |
-16.51 |
-14.6 |
-11.28 |
0 |
| Weighted Average Shares
Out |
$73.21 M
|
$52.18 M
|
$24.81 M
|
$16.10 M
|
$13.42 M
|
$12.39 M
|
$11.81 M
|
$11.81 M
|
| Weighted Average Shares
Out Diluted |
$73.21 M
|
$52.18 M
|
$24.81 M
|
$16.10 M
|
$13.42 M
|
$12.39 M
|
$11.81 M
|
$11.81 M
|
| Link |
|
|
|
|
|
|
|
|
